Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Manag Care ; 20(2 Suppl): s45-60, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24717173

ABSTRACT

Current challenges in the management of multiple myeloma (MM) include the changing treatment landscape and the need for better care coordination and improved communication. A roundtable meeting involving key stakeholders (physicians, nurses, pharmacists, managed care professionals, pharmaceutical industry professionals, and patient care advocates) was held to discuss challenges in the management of MM and evolving strategies to address these challenges and improve quality of care for patients with MM. Interventions discussed included the use of a treatment pathway to standardize treatment, decrease costs, and possibly increase efficacy by encouraging adherence to treatment guidelines whenever possible, and the use of an oncology medical home (OMH) to facilitate communication among treatment providers. Challenges to the successful implementation of treatment pathways include the rapid introduction of new therapies and the need to balance efficacy and value. It was stressed that treatment pathways must not prioritize profits over the health and welfare of the patient. Considerations related to the implementation of the OMH include the identification of appropriate measures to evaluate quality, value, and outcomes, and the provider implementation costs related to the OMH model.


Subject(s)
Managed Care Programs , Multiple Myeloma/therapy , Benchmarking , Biomarkers, Tumor/analysis , Critical Pathways , Diagnostic Imaging , Disease Progression , Glycoproteins/analysis , Humans , Multiple Myeloma/diagnosis , Multiple Myeloma/epidemiology , Neoplasm Staging , Paraproteinemias/diagnosis , Patient-Centered Care , Prognosis , Quality of Health Care , Reimbursement Mechanisms , Serum Albumin , Tumor Burden , United States/epidemiology , beta 2-Microglobulin/blood
5.
Am Health Drug Benefits ; 5(4): 202-17, 2012 Jul.
Article in English | MEDLINE | ID: mdl-24991320

ABSTRACT

Approximately 200 oncologists, payers, employers, managed care executives, pharmacy benefit managers, and other healthcare stakeholders convened in Houston, TX, on March 28-31, 2012, for the Second Annual Conference of the Association for Value-Based Cancer Care (AVBCC). The mission of the conference was to align the various perspectives around the growing need of defining value in cancer care and developing strategies to enhance patient outcomes. The AVBCC conference presented a forum for the various viewpoints from all the stakeholders across the cancer care continuum, featuring more than 20 sessions and symposia led by nearly 30 oncology leaders. The discussions focused on current trends and challenges in optimizing value in oncology by reducing or controlling cost while improving care quality and patient outcomes, introducing emerging approaches to management and tools that providers and payers are using to enhance cancer care collaboratively. The AVBCC Second Annual Conference was opened by a Steering Committee discussion of 11 panel members who attempted to define value in cancer care and articulated action steps that can help to implement value into cancer care delivery. The following summary represents highlights from the Steering Committee discussion, which was moderated by Gene Beed, MD, and Gary M. Owens, MD.

SELECTION OF CITATIONS
SEARCH DETAIL
...